Patient Demographic and Baseline Disease Characteristics
| . | Filgrastim . | SCF and Filgrastim . | Total . |
|---|---|---|---|
| N | |||
| 55 | 160 | 215 | |
| Sex (%) | |||
| Male | |||
| 1 (2) | 1 (1) | 2 (1) | |
| Female | |||
| 4 (98) | 159 (99) | 213 (99) | |
| Race (%) | |||
| White | |||
| 48 (87) | 132 (83) | 180 (84) | |
| Black | |||
| 0 (0) | 7 (4) | 7 (3) | |
| Hispanic | |||
| 5 (9) | 13 (8) | 18 (8) | |
| Asian | |||
| 1 (2) | 7 (4) | 8 (4) | |
| Other | |||
| 1 (2) | 1 (1) | 2 (1) | |
| Age (yr) | |||
| Median | |||
| 45 | 44 | 45 | |
| Minimum/maximum | |||
| 29/64 | 25/64 | 25/64 | |
| Weight (kg) | |||
| Median | |||
| 63.6 | 66.5 | 66 | |
| Minimum/maximum | |||
| 47.8/108.2 | 40.8/147.7 | 40.8/147.7 | |
| Stage (%) | |||
| II | |||
| 10 (18) | 32 (20) | 42 (20 | |
| IIIA | |||
| 15 (27) | 39 (24) | 54 (25) | |
| IIIB | |||
| 11 (20) | 22 (14) | 33 (15) | |
| IV | |||
| 19 (35) | 67 (42) | 86 (40) | |
| Previous radiotherapy (%) | |||
| No | |||
| 40 (73) | 124 (79) | 164 (77) | |
| Yes | |||
| 15 (27) | 33 (21) | 48 (23) |
| . | Filgrastim . | SCF and Filgrastim . | Total . |
|---|---|---|---|
| N | |||
| 55 | 160 | 215 | |
| Sex (%) | |||
| Male | |||
| 1 (2) | 1 (1) | 2 (1) | |
| Female | |||
| 4 (98) | 159 (99) | 213 (99) | |
| Race (%) | |||
| White | |||
| 48 (87) | 132 (83) | 180 (84) | |
| Black | |||
| 0 (0) | 7 (4) | 7 (3) | |
| Hispanic | |||
| 5 (9) | 13 (8) | 18 (8) | |
| Asian | |||
| 1 (2) | 7 (4) | 8 (4) | |
| Other | |||
| 1 (2) | 1 (1) | 2 (1) | |
| Age (yr) | |||
| Median | |||
| 45 | 44 | 45 | |
| Minimum/maximum | |||
| 29/64 | 25/64 | 25/64 | |
| Weight (kg) | |||
| Median | |||
| 63.6 | 66.5 | 66 | |
| Minimum/maximum | |||
| 47.8/108.2 | 40.8/147.7 | 40.8/147.7 | |
| Stage (%) | |||
| II | |||
| 10 (18) | 32 (20) | 42 (20 | |
| IIIA | |||
| 15 (27) | 39 (24) | 54 (25) | |
| IIIB | |||
| 11 (20) | 22 (14) | 33 (15) | |
| IV | |||
| 19 (35) | 67 (42) | 86 (40) | |
| Previous radiotherapy (%) | |||
| No | |||
| 40 (73) | 124 (79) | 164 (77) | |
| Yes | |||
| 15 (27) | 33 (21) | 48 (23) |
The 5 patients who received SCF alone are included with the SCF and filgrastim patients. Numbers in parentheses indicate percentages.